Jindike faces delisting risk amid flu vaccine woes, East Money reports

Jindike (金迪克) faces the risk of delisting as it struggles with the flu vaccine dilemma, according to East Money. The company previously missed the window for scaled trivalent flu vaccine sales, sending shares down 20%.

Detected & updated continuously · Source: Nebula